Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Surgery. 2023 Jan;173(1):138-145. doi: 10.1016/j.surg.2022.07.031. Epub 2022 Oct 14.
Hyperparathyroidism persists in many patients after kidney transplantation. The purpose of this study was to evaluate the association between post-transplant hyperparathyroidism and kidney transplantation outcomes.
We identified 824 participants from a prospective longitudinal cohort of adult patients who underwent kidney transplantation at a single institution between December 2008 and February 2020. Parathyroid hormone levels before and after kidney transplantation were abstracted from medical records. Post-transplant hyperparathyroidism was defined as parathyroid hormone level ≥70 pg/mL 1 year after kidney transplantation. Cox proportional hazards models were used to estimate the adjusted hazard ratios of mortality and death-censored graft loss by post-transplant hyperparathyroidism. Models were adjusted for age, sex, race/ethnicity, college education, parathyroid hormone level before kidney transplantation, cause of kidney failure, and years on dialysis before kidney transplantation. A Wald test for interactions was used to evaluate the risk of death-censored graft loss by age, sex, and race.
Of 824 recipients, 60.9% had post-transplant hyperparathyroidism. Compared with non-hyperparathyroidism patients, those with post-transplant hyperparathyroidism were more likely to be Black (47.2% vs 32.6%), undergo dialysis before kidney transplantation (86.9% vs 76.6%), and have a parathyroid hormone level ≥300 pg/mL before kidney transplantation (26.8% vs 9.5%) (all P < .001). Patients with post-transplant hyperparathyroidism had a 1.6-fold higher risk of death-censored graft loss (adjusted hazard ratio = 1.60, 95% confidence interval: 1.02-2.49) compared with those without post-transplant hyperparathyroidism. This risk more than doubled in those with parathyroid hormone ≥300 pg/mL 1 year after kidney transplantation (adjusted hazard ratio = 4.19, 95% confidence interval: 1.95-9.03). The risk of death-censored graft loss did not differ by age, sex, or race (all P > .05). There was no association between post-transplant hyperparathyroidism and mortality.
The risk of graft loss was significantly higher among patients with post-transplant hyperparathyroidism when compared with patients without post-transplant hyperparathyroidism.
甲状旁腺功能亢进症在许多肾移植患者中持续存在。本研究旨在评估移植后甲状旁腺功能亢进症与肾移植结局之间的关系。
我们从 2008 年 12 月至 2020 年 2 月在一家机构接受肾移植的成年患者前瞻性纵向队列中确定了 824 名参与者。从病历中提取肾移植前后甲状旁腺激素水平。将肾移植 1 年后甲状旁腺激素水平≥70pg/ml 定义为移植后甲状旁腺功能亢进症。使用 Cox 比例风险模型估计移植后甲状旁腺功能亢进症与死亡率和死亡相关移植物丢失的调整后风险比。模型调整了年龄、性别、种族/民族、大学教育、肾移植前甲状旁腺激素水平、肾衰竭原因和肾移植前透析年限。使用 Wald 检验评估年龄、性别和种族对死亡相关移植物丢失的风险。
在 824 名受者中,60.9%患有移植后甲状旁腺功能亢进症。与非甲状旁腺功能亢进症患者相比,甲状旁腺功能亢进症患者更有可能为黑人(47.2%比 32.6%)、在肾移植前接受透析(86.9%比 76.6%)和在肾移植前甲状旁腺激素水平≥300pg/ml(26.8%比 9.5%)(均 P<.001)。与无甲状旁腺功能亢进症患者相比,甲状旁腺功能亢进症患者死亡相关移植物丢失的风险增加 1.6 倍(调整后风险比=1.60,95%置信区间:1.02-2.49)。在肾移植后 1 年甲状旁腺激素≥300pg/ml 的患者中,这种风险增加了两倍多(调整后风险比=4.19,95%置信区间:1.95-9.03)。死亡相关移植物丢失的风险在年龄、性别或种族之间无差异(均 P>.05)。甲状旁腺功能亢进症与死亡率之间没有关联。
与无甲状旁腺功能亢进症患者相比,甲状旁腺功能亢进症患者的移植物丢失风险显著增加。